Showing 221-230 of 3932 results for "".
The Microbiome: What Do We Know Now?
https://practicaldermatology.com/topics/atopic-dermatitis/the-microbiome-what-do-we-know-now/23122/Questions and answers about the microbiome and its role in influencing cutaneous health.What Every Dermatologist Must Know About the History of Black Hair
https://practicaldermatology.com/topics/hair-nails/what-every-dermatologist-must-know-about-the-history-of-black-hair/23996/Knowledge of the historical, cultural, and social significance of hairstyles of Black patients may reduce implicit bias amongst dermatologists. In this article, Brooke Jackson, MD, FAAD, and Aliya Rodriguez, BS, explore the unique history and cultral impact of black hair.The New Thinking on Psoriasis
https://practicaldermatology.com/topics/psoriasis/the-new-thinking-on-psoriasis/20979/Psoriasis is a cutaneous manifestation of a systemic disease.What Does Efficacy Cost? Evidence for Relative Cost-Effectiveness of Biologic Therapies for Psoriasis
https://practicaldermatology.com/topics/psoriasis/what-does-efficacy-cost-evidence-for-relative-cost-effectiveness-of-biologic-therapies-for-psoriasis/23128/Despite high costs, evidence suggests that biologics are cost-effective options for moderate to severe psoriasis because of their efficacy.Psoriasis in Sensitive Areas
https://practicaldermatology.com/topics/psoriasis/psoriasis-in-sensitive-areas/23868/Treatment updates and tips for communicating with patients.Upadacitinib and Cardiovascular Events in AD
https://practicaldermatology.com/issues/october-2025/upadacitinib-and-cardiovascular-events-in-ad/39755/A recent review examined whether upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis (AD) and other chronic inflammatory diseases, may—despite a boxed warning to the contrary—confer cardioprotective and thromboprotective effects.Atopic Dermatitis: A Review of Common Comorbidities
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-a-review-of-common-comorbidities/23352/It is important to acknowledge and identify comorbidities to successfully manage AD and improve patient quality of life.Practical Considerations for Treating Psoriasis: Focus on Secukinumab
https://practicaldermatology.com/topics/psoriasis/practical-considerations-for-treating-psoriasis-focus-on-secukinumab/20841/Your Destination for the Latest Developments in #Dermatology in Print and Online
https://practicaldermatology.com/topics/practice-management/your-destination-for-the-latest-developments-in-dermatology-in-print-and-online/20903/Analyzing Safety Data From Level Up
https://practicaldermatology.com/series/the-practical-dermatology-podcast/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versu